nach oben

Erschienen in:

2011 | OriginalPaper | Buchkapitel

2. Pharmakodynamik

verfasst von : Prof. Dr. Bernd Antkowiak, Prof. Dr. Dr. Ingolf Cascorbi

Erschienen in: Pharmakotherapie in der Anästhesie und Intensivmedizin

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Gruppe der Anästhetika gehören Substanzen mit sehr unterschiedlichen chemischen Strukturformeln (◘Abb. 2.1). Hierzu zählen Hydrocarbone (Chloroform, Halothan), Derivate des Ether (Isofluran, Desfluran, Sevofluran), Phenole (Propofol), Imidazolderivate (Etomidat, Dexmedetomidin), Phencyclidine (Ketamin), Steroide (Alphaxalone), Barbiturate (Thiopental), Benzodiazepine (Midazolam) und Edelgase (Xenon).

[1]

Antkowiak, B (2001) How do gerneral anaesthetis work? Neuro-wissenschaften 88:201–213CrossRef

[2]

Cascorbi I (2006) Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Ther 112:457–473PubMedCrossRef

[3]

Daly AK (2009) Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Med 1:10PubMedCrossRef

[4]

Drago A, De Ronchi D, Serretti A (2009) Pharmacogenetics of antidepressant response: an update. Hum Genomics 3:257–274PubMedCrossRef

[5]

Drexler B, Grasshoff C, Rudolph U, Unertl K, Antkowiak B (2006) The GABA(A) receptor family : Possibilities for the development of better anesthetics. Anaesthesist 55:287–295PubMedCrossRef

[6]

Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57: 119–137PubMedCrossRef

[7]

Franks NP (2006) Molecular targets underlying general anaesthesia. Brit J Pharmacol 147: S72–S81CrossRef

[8]

Grasshoff C, Rudolph U, Antkowiak B (2005) Molecular and systemic mechanisms of general anaesthesia: the,multi-site and multiple mechanisms' concept. Curr Opin Anaesth 18:386–391CrossRef

[9]

Hemmings HC, Akabas MH, Goldstein PA et al. (2005) Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci 26:503–510PubMedCrossRef

[10]

Hughes AR, Spreen WR, Mosteller M et al. (2008) Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J 8:365–374PubMedCrossRef

[11]

Kaiser R, Sezer O, Papies A et al. (2002) Patient-tailored anti-emetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811PubMedCrossRef

[12]

Klotz U (2006) Clinical impact of CYP2C19 polymorphism on the action of proton pump inhibitors: a review of a special problem. Int J Clin Pharmacol Ther 44:297–302PubMed

[13]

La Du BN, Bartels CF, Nogueira CP, Arpagaus M, Lockridge O (1991) Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing. Cell Mol Neurobiol 11:79–89PubMedCrossRef

[14]

Liggett SB, Mialet-Perez J, Thaneemit-Chen S et al. (2006) A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci USA 103:11288–11293PubMedCrossRef

[15]

Link E, Parish S, Armitage J et al. (2008) SLCO1B1 variants and statin-induced myopathy-a genomewide study. N EngI J Med 359:789–799CrossRef

[16]

Loscher W, Delanty N (2009) MDR1/ABCB1 polymorphisms and multidrug resistance in epilepsy: in and out of fashion. Pharma-cogenomics 10:711–713CrossRef

[17]

Lotsch J, Geisslinger G (2005) Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 11:82–89PubMedCrossRef

[18]

Lotsch J, Geisslinger G (2006) Current evidence for a genetic modulation of the response to analgesics. Pain 121:1–5PubMedCrossRef

[19]

Mariani G, Fasolo A, De Benedictis E, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6: 93–104PubMedCrossRef

[20]

Nagele P, Zeugswetter B, Wiener C et al. (2008) Influence of methylenetetrahydrofolate reductase gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia. Anesthesiology 109:36–43PubMedCrossRef

[21]

Niemi M (2007) Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8:787–802PubMedCrossRef

[22]

Rau T, Wuttke H, Michels LM et al. (2009) Impact of the CYP2D6 genotype on the clinical effects of metoprolol: a prospective longitudinal study. Clin Pharmacol Ther 85:269–272PubMedCrossRef

[23]

Robinson RL, Anetseder MJ, Brancadoro V et al. (2003) Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing? Eur J Hum Genet 11:342–348PubMedCrossRef

[24]

Rudolph U, Antkowiak B (2004) Molecular and neuronal substrates for general anaesthetics. Nature Rev Neuroscience 5: 709–720CrossRef

[25]

Simon T, Verstuyft C, Mary-Krause M et al. (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N EngI J Med 360:363–375CrossRef

[26]

Small KM, Wagoner LE, Levin AM, Kardia SL, Liggett SB (2002) Synergistic polymorphisms of betal- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347:1135–1142PubMedCrossRef

[27]

Sonner JM, Antognini JF, Dutton RC et al. (2003) Inhaled anesthetics and immobility: mechanisms, mysteries, and minimum alveolar anesthetic concentration. Anesth Anal 97:718–740CrossRef

[28]

Steimer W, Zopf K, von Amelunxen S et al. (2005) Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 51:376–385PubMedCrossRef

[29]

Urban BW (2002) Current assessment of targets and theories of anaesthesia. Br J Anaesth 89:165–183

[30]

Urban BW, Bleckwenn M (2002) Concepts and correlations relevant to general anaesthesia. Br J Anaesth 89:3–16PubMedCrossRef

[31]

Urban BW, Bleckwenn M, Barann M (2006) Interactions of anesthetics with their targets: Non-specific, specific or both? Pharmacology therapeutics 111: 729–770PubMedCrossRef

[32]

Yin T, Maekawa K, Kamide K et al. (2008) Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res 31:1549–1557PubMedCrossRef

Titel: Pharmakodynamik
verfasst von: Prof. Dr. Bernd Antkowiak
Prof. Dr. Dr. Ingolf Cascorbi
Verlag: Springer Berlin Heidelberg
Buch: Pharmakotherapie in der Anästhesie und Intensivmedizin
Print ISBN: 978-3-540-79155-3

Electronic ISBN: 978-3-540-79156-0

Copyright-Jahr: 2011
DOI: https://doi.org/10.1007/978-3-540-79156-0_2

Neu im Fachgebiet AINS

23.04.2024 | Appendizitis | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

2. Pharmakodynamik

Zusammenfassung

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet AINS

Hinter dieser Appendizitis steckte ein Erreger

Ärztliche Empathie hilft gegen Rückenschmerzen

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

S3-Leitlinie zu Pankreaskrebs aktualisiert

Update AINS